Graft vs. host disease (GVHD) can occur after a stem cell transplant from a donor. Transplants replace unhealthy cells with healthy blood-forming cells, which can treat some cancers. GVHD happens when ...

Fred Hutch bone marrow transplant and GVHD expert Dr. Geoffrey Hill explains how a new approach has changed the BMT landscape, where research is headed next Now, more than 1.5 million transplants have ...

The European Medicines Agency (EMA) has recommended the refusal of marketing authorization for Rezurock (belumosudil) for treating patients 12 years or older with chronic graft-vs-host disease (cGvHD) ...

Is Unmutated IgG1 a Wrong Choice for Therapeutic Antibodies Targeting Immune Checkpoints? Lessons From the Clinical Failures of the First Anti–TIGIT Antibodies While overall survival (OS) ostensibly ...

SEATTLE — March 5, 2025 — Below are summaries of recent Fred Hutch Cancer Center research findings, patient stories and other news. March is the awareness month for colorectal cancer and multiple ...

Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non–Small Cell Lung Cancer: The Phase III PACIFIC-2 Study To determine whether sirolimus (SIR) and cyclosporine ...

Graft-versus-host disease (GVHD) following liver transplantation remains a rare but devastating complication, characterised by donor immunocompetent cells initiating an immune attack against host ...

Equillium, Inc. (NASDAQ:EQ) released topline data on Thursday from the Phase 3 EQUATOR study. The study evaluated itolizumab in the first-line treatment of patients with acute graft-versus-host ...

Patients who underwent hematopoietic cell transplantation for sickle cell disease saw high rates of survival without disease symptoms and low rates of severe side effects or complications years after ...